Role of serum (1,3)‐β‐d‐glucan assay in early diagnosis of invasive fungal infections in a neonatal intensive care unit

Abstract

ObjectivesTo study the microbiological pattern of late onset neonatal sepsis cultures and to assess the diagnostic performance of serum (1,3)‐β‐d‐glucan level for early diagnosis of invasive fungemia in high‐risk infants admitted to a neonatal intensive care unit. MethodsA prospective multicenter clinical trial conducted on infants at high risk for invasive fungal infections, with suspected late onset sepsis, admitted to a neonatal intensive care unit at Mansoura University Children's Hospital and Mansoura General Hospital between March 2014 and February 2016. ResultsA total of 77 newborn infants with high risk of invasive fungal infection were classified based on blood culture into three groups: no fungemia (41 neonates with proven bacterial sepsis), suspected fungemia (25 neonates with negative blood culture), and definite fungemia group (11 neonates with culture‐proven Candida). The growing organisms were Klebsiella spp. (14/54); Escherichia coli (12/54); Staphylococcus spp. (12/54; coagulase‐negative Staphylococcus [9/54]; Staphylococcus aureus [3/54]); Pseudomonas aerouginosa (3/54); and Proteus spp. (2/54). Moreover, 11/54 presented Candida. Serum (1,3)‐β‐d‐glucan concentration was significantly lower in the no fungemia group when compared with the definite fungemia group. The best cut‐off value of (1,3)‐β‐d‐glucan was 99pg/mL with sensitivity, specificity, positive predictive value, negative predictive value, and accuracy of 63.6%, 95.1%, 77.8%, 90.7%, and 88.5%, respectively. Conclusion(1,3)‐β‐d‐glucan assay has a limited sensitivity with excellent specificity and negative predictive value, which allow its use as an aid in exclusion of invasive neonatal fungal infection. Accurate diagnosis and therapeutic decisions should be based on combining (1,3)‐β‐d‐glucan assay with other clinical, radiological, and microbiological findings.